Physician profile
Peter B Boggs
NPI 1447217252
$2,790.89
in general payments reported to CMS, 2019-2025
18 companies · $795 in 2025
The $795 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $211 · 2021: $391 · 2022: $347 · 2023: $61.60 · 2024: $273 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $924.54 | 2019-2025 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $387.27 | 2019-2025 | Dupixent |
| Genzyme Corporation | $322.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $267.31 | 2019-2025 | Nucala |
| Csl Behring | $170.15 | 2019-2025 | Andembry |
| Biocryst US Sales Co., LLC | $152.96 | 2022-2024 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $125.00 | 2025 | Dawnzera |
| Amgen INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $86.32 | 2023-2025 | |
| Boston Scientific Corporation | $51.64 | 2024 | Versacross Access Solution |
| Takeda Pharmaceuticals U.S.A., INC. | $40.83 | 2020-2024 | Takhzyro |
| Phadia US INC. | $30.82 | 2020 | |
| Pfizer INC. | $22.36 | 2024 | |
| Kaleo, INC. | $17.98 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $17.93 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $17.00 | 2021 | |
| Pharming Healthcare, INC. | $15.90 | 2019 | |
| Cycle Pharmaceuticals INC | $15.12 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.